Does TAVR with a self-expanding prosthesis improve survival at 1 year compared to surgical aortic-valve replacement in patients with severe aortic stenosis at increased surgical risk?
Patients with severe aortic stenosis who are at increased surgical risk
Transcatheter aortic-valve replacement (TAVR) with a self-expanding bioprosthesis
Surgical aortic-valve replacement
Survival at 1 yearhard clinical
In high-risk patients with severe aortic stenosis, TAVR with a self-expanding prosthesis significantly improves 1-year survival compared to surgical aortic-valve replacement.
In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aortic-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aortic-valve replacement. (Funded by Medtronic; U.S. CoreValve High Risk Study ClinicalTrials.gov number, NCT01240902.).
Building similarity graph...
Analyzing shared references across papers
Loading...
David Adams
Jeffrey J. Popma
Michael J. Reardon
New England Journal of Medicine
University of Michigan
Duke Medical Center
University of Pittsburgh Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Adams et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69d5719e75589c71d767e3b1 — DOI: https://doi.org/10.1056/nejmoa1400590
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: